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Background: Hyaluronic acid (HA) is of importance due to its diverse applications in pharmaceuticals and medical
devices such as dermal filler, adhesion barriers, carrier for cells and bioactive molecules as well as scaffold
biomaterials for tissue engineering. Evaluations of purification and biocompatibility of HA are required for its
applications to biomaterials.
Results: After synthesizing HA by fermentation of streptococcus zooepidemicus for 25 hr, extensively purification of
the fermented broth was performed to remove impurities using a filtration process for insoluble components and
cells, and diverse adsorbents for soluble impurities. Its in vitro biocompatibility has been evaluated by measurement
of cell counting and assay of cell live and dead. 60% yield of white HA powder was obtained, having 15–17 dL/g
intrinsic viscosity with a molecular weight of approximately 1,000 kDa. While low molecular weight impurities and
insoluble impurities were successfully removed using a ultrafiltration membrane with 50 KDa molecular weight cut,
endotoxins, high molecular weight proteins and nucleic acids were removed from the broth by employing
adsorbents such as alumina and activated carbons. Alumina showed the best results for the removal of endotoxins,
all of the activated carbons were very effective in the removal of high molecular weight proteins and nucleic acids.
The purified HA solution showed excellent cell compatibility with no cell damages as observed by both
measurement of cell proliferation and observation of cell viability.
Conclusions: We obtained high molecular weight HA with excellent biocompatibility as judged by both
measurement of cell proliferation and viability, indicating high possibility of its applications to biomaterials.
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Hyaluronic acid (HA) is a linear anionic, non-sulfated,
high molecular weight glycosaminoglycan with alterna-
ting D-glucuronic acid and N-acetyl-D-glucosamine. HA
is distributed natively as a component of extracellular
matrix in connective, epithelial and neutral tissues in
body. HA has several important physico-chemical and
biological properties including lubricity, visco-elasticity,
water retention, biocompatibility, cell proliferation, mor-
phogenesis, inflammation and wound repair as well as
specific signal transduction and cellular interactions
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unless otherwise stated.CD168 [1-3]. HA can be degraded by both reactive oxygen
intermediates and hyaluronases, which are synthesized by
macrophages, fibroblasts and endothelial cells [4,5].
HA has been produced by either extraction from rooster
combs, the highly viscous vitreous humor of bovine eyes
[6,7] and human umbilical cord or bacterial fermentation
of group C streptococci, namely hemolytic streptococci
[8]. Purification of medium containing HA products has
been achieved using a variety of different methods [9-14],
including filtration and adsorption. These methods nor-
mally result in the purification of HA with molecular
weights ranging from 104 to 107 Da [14]. Various forms of
purified HA have been used in different commercial prod-
ucts such as cosmetics [15], eye drops [16], food additives
[17], medical devices [1], pharmaceutics [18-20], tissue
engineering [21,22] and cell therapy [23]. For example,
Viscoat has been used as a viscosurgical agent by Alcon
Co. (TX, USA) and for visco-supplementation in arthriticd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in Italy utilized HA with moderate molecular size as a
visco-supplement, Genzyme Co. (MA, USA) and Q-Meds
used cross-linked HA products as visco-supplements. HA
is currently being investigated for use as a bioactive mate-
rial for plastic fillers to eliminate facial wrinkles, a carrier
to deliver stem cells, bioactive materials to treat specific
diseases and a scaffold for tissue engineering of bone, car-
tilage, blood vessel and nerves [21,22].
Recently demands for HA products from bacterial fer-
mentation have significantly increased because of both
their increased uses as medical devices and the immune
issues that occurred from the use of animal based HA.
Due to the both high price of HA and the high standard
requirements of its applications in medical products,
high quality HA products rather than high quantity have
been the primary criteria used when selecting the bac-
terial strains used for HA production and the methods
of HA purification. In this study, we examined the
effects of various adsorbents such as activated carbons
and alumina on the purification of fermented HA broth
as well as biocompatibility tests. Schematic processes of
bacterial fermentation and HA separations and charac-
terizations are shown in Figure 1. The HA obtained in
this study may expand the potential application of HA
in biomaterials targeting on the areas of cell therapy, tis-
sue engineering and medical devices.Figure 1 Schematic processes of bacterial fermentation and HA
separations and characterizations.Methods
Materials
Streptococcus zooepidemicus, mutant bacterial strains, were
employed in the fermentation experiments. The yeast
extract and sodium chloride were purchased from Beckton
Dickinson (USA) and Merk Co. (Germany), respectively,
and glucose and potassium phosphate were obtained
from Sigma Co. (USA). L-Glutamate and membrane filter
were obtained from Daesang Co. (Korea) and Begerow
(Germany), respectively. Ultra-filtration membrane filters
and diafiltration membranes with a molecular weight cut
offs 30 and 50 KDa were purchased from Milipore Co
(MA, USA). The different adsorbents including alumina
and eight activated carbons were purchased from Baikowski
Co. (Japan) and Norit Co. (Netherland), respectively. The
specific physicochemical properties such as BET, pH, mois-
ture, particle size, iodine number and morphologies of the
absorbents are described in Table 1.
Fermentation and analysis of the properties of the
fermenting broth
Streptococcus zooepidemicus was fermented in a bioreactor
(5 L, Marubishi Inc.) at 37°C and 300 rpm for 25 hr with 1.0
vvm aeration to obtain hyaluronic acid, which have been
reported well by numerous companies and researchers, in-
cluding Akdamar HA and Volpi N [11-12]. The complex
media under an aerobic condition that was used as the fer-
menting broth consisted of yeast extract (15 ~ 25 g/L), potas-
sium phosphate (2.5 g/L), glucose (60 ~ 80 g/L), magnesium
sulfate (3 g/L), sodium chloride (5 g/L) and L-glutamate
(7 g/L). The residual L-glucose in the fermenting broth was
analyzed using 1 ml in a biochemical analyzer (MBI 7200
model, YSI Co., USA) and the optical density of the broth was
measured with a Spectrophotometer (UV2450, Simadzu Co.,
Japan) at an wavelength of 600 nm after a 10 fold dilution. The
broth’s viscosity was measured using a rotary viscometer (LV
type, Brookfield Co.) and 400mLof the solution.
Purification
Removal of cells
The bacterial strains and insoluble impurities in the
highly viscous broth were removed by filtering with a
depth filter (KD7, Begerow Co.) that had a 1.5 μm nom-
inal retention rate after mixing with either 1, 3 or 5%
diatomaceous earth (v/v). The efficacy of the broth filtra-
tion was confirmed by measuring the presence of bac-
teria with a Spectrophotometer (UV2450, Simadzu Co.,
Japan) at a wavelength of 600 nm.
Diafiltration purification
Diafiltration was used for the removal of broth compo-
nents, metabolic products and low molecular weight im-
purities from 5 L of broth. This process was conducted
using a tangential flow filtration method by employing
Table 1 Physical properties of the adsorbents employed in the adsorption process
Model name Morphology Particle size
(μm; d10, d50, d90)*
Iodine number Methylene blue
adsorption (g/100 g)
B.E.T.** (m2/g) pH Moisture (%)
Darco KB-B Powder 4, 15, 40 - 42 2050 2 ≤15%
Norit CN1 Powder 7, 30, 76 - 29 1400 5.5 ~ 8 ≤15%
Norit SX Plus Powder 6, 20, 80 1050 22 1100 Neutral ≤10%
Norit SX 1G Powder 5, 25, 90 900 18 1000 Neutral ≤10%
Norit C Gran Granule 0.85 mm~ 1.7 mm*** - 30 1400 2 ~ 8 ≤15%
Norit GAC 1240+ Granule 0.43 mm~ 2.0 mm*** 1025 22 1125 Neutral ≤3%
Norit C Extra USP Powder 4, 23, 100 1100 22 1200 Neutral ≤10%
Norit A Supra EUR Powder 4, 20, 100 1550 41 1700 Neutral ≤10%
Alumina Powder 2.5, 6, 10 - - 103 - -
*The particle sizes (diameter) indicated that their actual sizes are less than those given.
**Total surface area.
***More than 95% have the granule sizes indicated.
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the bacterial strains and insoluble impurities. The sample
was then diluted by a factor of 2 using deionized water.
Diafiltration was performed by pumping the solution
through the poly(ether sulphone) ultrafilter cassette with a
dimension of 0.5 m2 and a molecular weight cut-off
of either 30 or 50 kDa (PR sterile 40, Begerow Inc.,
Germany). After defining the number of the diafiltration
purification as the number of alternating processes of both
concentration and dilution, both the permeate and con-
ductivity and the concentration of residual lactate were
measured using a conductivity meter (Seveneasy; Mettler-
Toledo, Swizerland) and the biochemical analyzer (MBI
7200; YSI Inc., USA), respectively. The concentration of
residual lactates was measured by feeding 1 mL into the
biochemical analyzer and measuring the electrical signals
from the residual lactates, which were produced as a
metabolic byproduct during the fermenting process. The
electrical signals were measured by the biochemical
analyzer during induction of lactates degradation by
L-lactate oxidases. The volume of the permeate solution
filtered from the membrane was measured in a dimension
of L/h/m2 to check the buffer change time during
diafiltration.
Purification by adsorbents
High molecular weight impurities were removed by
adding different adsorbents to the diafiltrated broth.
After addition of 2% adsorbent (w/v) into 1,000 mL of
the diafiltrated broth, the solution was stirred with a stir-
rer (RZR2021, Heidolph Inc., Germany) for 10 hr. The
adsorbents were then removed using a 0.45 μm filter
(PR sterile 40, Begerow Inc., Germany).
Recovery of the hyaluronic acid in powder
Solidification of the HA sample was achieved by adding
3 L of acetone to the adsorption-processed solution. TheHA powder was recovered and dried after filtration of
the solidified HA with a 100 μm mesh (CISA, Spain).
The HA yield was determined to be about 60%, which
was measured by comparing the weight of the dry HA
with that of the fermented weight.
Analysis
Verification of hyaluronic acid powder was performed
using the analytical methods described in both the
European pharmacopoeia and Korean pharmacopoeia,
which included measuring the residual levels of endo-
toxins, proteins, nucleic acids and small particles.
Endotoxin analysis
The kinetic chromogenic method (Kinetic-QCL Chromo-
genic LAL assay, Lonza, USA) was used to measure the
amount of residual endotoxin. After syntheses of both
standard and test solutions according to the procedures
suggested by the vendor, the LAL kinetic chromogenic re-
agent was added and its optical density was measured at a
wavelength of 405 nm using a microplate meter. Two mL
standard solutions were obtained by diluting the standards
to 0.005, 0.05, 0.5, 5 EU/mL with the LAL reagent water
(Lonza Co., USA). The test solution was prepared by di-
luting the sample solution to the lowest possible level to
minimize the effect of inhibition factors. The LAL reagent
was prepared by adding up LAL reagent water to the LAL
kinetic chromogenic reagent.
Protein analysis
Examination of residual high molecular weight proteins in
the hyaluronic acid powder was performed according to
the protein tests recommended by the Korean phar-
macopoeia. The test solution was prepared by dissolving
0.1 g HA powder in 20 mL deionized water. BSA was used
as the reference solution and the BSA concentrations used
were 1, 3, 5, 7 and 10%. Test and standard solutions were
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After reacting with 0.5 mL of the phosphomolybdotunstic
reagent for 30 min, the solution’s optical density was mea-
sured at a wavelength of 750 nm, which was used to
calculate the concentrations of residual proteins. The
phosphomolybdotunstic reagent was obtained by refluxing
for 10 hr in a reflux condenser after the addition of 100 g
sodium tunstate and 25 g sodium molybdate, and then
100 mL hydrogen chloride and 50 mL phosphonic acid.
To remove excess bromine, the sample was boiled for
15 min after the addition of 150 g lithum sulfate, 50 mL
water and bromine. Water was added to a final volume of
1,000 mL and then the sample was filtered. The cupri-
tartaric solution was prepared by mixing 50 mL sodium
carbonate with 0.1 mL of a solution that was previously
prepared by dissolving 1.0 g copper sulfate and 2.0 g so-
dium tartarate in 100 mL deionized water. The 100 mL
sodium carbonate solution was obtained by dissolving
4.0 g sodium carbonate in 0.2 M NaOH.
Nucleic acid analysis
Residual nucleic acid was analyzed in either a liquid or
powder state. The amount of nucleic acid in the proces-
sing broth was obtained by measuring the optical density
of a 1 mL solution at a wavelength of 260 nm using
the Spectrophotometer (Simadzu Inc., Japan) and the
amount of nucleic acid in the powder was determined
by adding the powder to 30 mL 0.9% sodium chloride
solution and then measuring absorbance at 260 nm.
Measurement of micro-particles in the processing broth
Micro-particles in the processing broth after treatment
with diverse activated carbons were measured using a li-
quid particle counter (LS-200, Particle Measuring Systems
Inc., USA). In this analysis, 20 mL test solution either with
or without HA was added to the liquid particle counter as
well as solution containing 2% of the activated carbons
were fed in either granule or powder form.
Molecular weight of HA
The molecular weight of the dry HA was measured using
a Multi Angle Laser Light Scattering (MALS) detector
(DAWN, Wyatt Technology Co., US) and high per-
formance liquid chromatography (HPLC) (1200 series,
Agilent, Germany) (column: TSK G6000 PWXL, Tosoh,
Japan). A 0.02 ~ 0.03% HA solution was filtered through a
0.45 μm filter (Acrovisk, PALL, USA) and then injected
into the HPLC system with a glass syringe. The molecular
weights of the HA compounds were measured using a
multi-angle light scattering (MALS) detector.
Intrinsic viscosity
40 mL 0.005%, 0.010%, 0.015% and 0.020% HA solutions
were synthesized by dissolving the dry HA powder inbuffer solution (0.01 M) with 0.15 M sodium chloride at
pH 7. Relative viscosity was obtained by measuring the
flow time of the HA solution with a capillary viscometer
(Type 501 01, SI Analytics GmbH, Germany) and linear
least-square regression of the Martin equation.In vitro evaluation of HA samples
In vitro cell culture
MC3T3 cells, osteoblast precursor cell line, were in vitro
cultured in α-MEM media (Sigma Aldrich, USA) contain-
ing 10% fetal bovine serum and penicillin-streptomycin
(100 IU/mL) and gentamycin (2 L/mL) in an incubator
with 5% CO2 at 37°C. Sterilized HA solution (Hyalrheuma
Inj.; Hanmi Pharmaceutical Co., Pyeongtaek, Korea) was
loaded on a 24 well polystyrene tissue culture plate (Nunc
Co., USA). MC3T3 cells, 10,000 cells/well, were seeded on
the surface of 200 μl HA solution and cultured under
static conditions in an incubator with 5% CO2 at 37°C for
7 days.Cell proliferation assay
Cell adhesion and proliferation on the HA solution was
quantitatively measured by counting the number of cells
with a cell counting kit-8 (CCK-8; Dojindo: Japan) by a
microplate reader (Tecan: Australia). 100 μL solution of
CCK-8 was inserted into the 1 mL cell culture medium
and then the cell culture plate was incubated in 5% CO2
incubator at 37°C. After 4 hr, 100 μL α-MEM with
CCK-8 was aliquoted into a 96 well plate and then the
optical its density was measured at the wavelength of
450 nm [23].In vitro cell viability by live & dead assay
For observation of cytotoxicity of the HA solution, cell
viability on the HA solution was evaluated by Live &
Dead assay after in vitro cell culture with MC3T3 cells
for 7 days according to our previous report, by staining
with fluororescence dye [24].Results and discussion
Bacterial fermentation for HA production
Bacterial fermentation of streptococcus zooepidemicus in
the L-glucose bioreactor continued until complete con-
sumption of L-glucose in the culture broth. The fer-
mentor was operated at 37°C and 300 rpm for 25 hr
with 1.0 vvm aeration, which resulted in the production
of 6.0 ~ 6.5 g HA/L. The optical density of the fermented
solution ranged from 8.0 to 12.0 and the broth viscosity
processed at 35°C and 21 spindles was as approximately
8000 cP. The molecular weight of the HA obtained was
determined to be 900 ~ 1,100 kDa.
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Removal of bacteria and insoluble impurities
Bacteria strains and insoluble impurities were removed
by filtration of the fermented broth using different reten-
tion rates of the fibrillated cellulose fibers filter sheets
and the addition of different concentrations of earth soil.
The filter had three retention rate sizes of 0.6, 1.0.
1.5 μm, when 1, 3 and 5% earth soil concentrations
(w/v) were used. The effects of filtration on HA purifi-
cation are clearly shown in Table 2. Before filtration, the
fermented solution had an optical density of 5.30. How-
ever, after filtration, the optical densities were less than
0.1 for all the samples. By increasing the earth oil con-
centrations, the flow rates increased significantly (2.5,
5.3 and 10.0 L/hr at earth oil concentrations of 1, 3 and
5% earth oils) when filters with a nominal retention rate
of 0.6 μm were used. These increases in the flow rates
were applied to all other conditions such as 1.0 and 1.5
nominal retention rates of the filter sheets.
HA purification with diafiltration method
Next we removed impurities such as culture products
and broth components from the bacteria-free broth
through filtration. The extent of impurity removal was
evaluated by measuring membrane conductivity and
flow rates over the membrane pores, and the number of
diafiltration cycles.
Measurement of conductivity and flow rates of broth
We employed poly(ether sulphone) membranes with two
kinds of pore sizes, i.e. with molecular weight cut-off sizes
of both 30 and 50 KD, to measure the conductivity and
permeance of the membrane filters (Figure 2). The con-
ductivities of the two membranes were similar to each
other at the same number of diafiltration cycles, but the
values significantly decreased as the number of diafiltration
cycles was increased. More specifically, the conductivitiesTable 2 Removal of strains by filtration conditions









Before filtration - - 5.30 -
After filtration 0.6 1 0.06 2.5
0.6 3 0.05 5.3
0.6 5 0.03 10
1.0 1 0.05 3.7
1.0 3 0.07 6.2
1.0 5 0.03 9.3
1.5 1 0.06 5.8
1.5 3 0.02 8.5
1.5 5 0.02 13.3of the membranes with the 30 KD molecular weight
cut-off size decreased from 19.6 to 9.01, 4.01, 1.7 and
0.7 ms/cm for diafiltration cycles of 1, 2, 3 and 4, respec-
tively. However, the permeance of the membrane filters
were displayed a significant different behavior than the
conductivities. As expected, the peremances of the mem-
brane filters for both molecular weight cut-off sizes, i.e. 30
and 50 KDa, increased when the number of diafiltration
cycles was increased. The permeance of the membrane
filters with a 50 KDa molecular weight cut-off size in-
creased from 3.5 to 5.1, 7.6, 10.5 and 11.7 L/hr/m2, while
the permeance of the 30 kDa molecular weight cut-off size
increased from 1.7 to 2.6, 5.2, 7.1 and 7.9 L/hr/m2. These
results indicated that the membrane filters with higher mo-
lecular weight cut-off sizes and samples subject to more
diafiltration cycles had higher rates of permeate flow. The
reason for the increase in permeances by repeated diafiltra-
tions was previously shown to be due to the removal of air
entrapped in the membrane pores [24].
Removal of impurities by diafiltrations Next we mea-
sured membrane conductivity and lactate concentrations
in the broth samples that had been subjected to a dif-
ferent number of diafiltration cycles (Figure 3). As ex-
pected, both the conductivity of the membrane filter and
the concentrations of the sample decreased significantly
when the number of diafiltration cycles was increased.
When the conductivities decreased from 17.7 before dia-
filtration to 9.5, 4.8, 2.5, 1.2, 0.6, 0.3 and 0.1 by increa-
sing the filtration cycles from 1 to 8, the concentrations
of lactates in the samples decreased from 74.1 to 51.0,
34.0, 20.1, 11.0, 5.4, 2.3, 1.0 and 0.4, respectively. These
results showed that lactate impurities decreased to ap-
proximately 1% by repeating diafiltration 7 times.
Purification
The medium solutions that had been diafiltrated still
contained significant amounts of impurities including
colors (67.44 EU/mL) and endotoxins (77.73 μg/mL).
Therefore, the filtrated broth was further purified using
various adsorbents as described below.
Removal of endotoxin After removal of low molecular
weight proteins and other impurities through the diafiltra-
tion process, different adsorbents (2%), including the acti-
vated carbons and alumina, were used for the removal of
endotoxins, which were induced either in the processing
broth or from product sources and are known to be a
source of pyrogenicity in humans. Different amounts of
endotoxin absorbed onto the adsorbents depending on
the types of adsorbents. Among the employed absorbents,
alumina with the smallest BET value (103) removed the
highest level of endotoxins (99.7%) (Table 3). The other
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Figure 2 Conductivities and permeance of filtrate through the membrane filters over different cycles of diafiltration.
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endotoxins, ranging from 88 to 92%. Norit SX Plus and
1G, Norit C Gran and Norit GAC 1240+ were not eva-
luated in regards to removal of residual endotoxin because
of the residual colors of Norit SX Plus and 1G, membrane
filter blockage by Norit C Gran and metal corrosion by
Norit GAC 1240+.
Removal of proteins High molecular weight proteins,
which are metabolic byproducts in this study, were still
present in the processing broth. While low molecular
weight proteins were removed during the previous dia-
filtration process using a membrane with a molecular
weight cut-off of 50 KDa, high molecular weight proteins
needed to be removed using adsorbents. In contrast toFigure 3 Membrane conductivity and lactate concentrations in the peendotoxin removal, alumina removed only 87.8% of the
proteins, while the activated carbons such as Darco KB-B,
Norit CN1, Norit A Supra EUR and Norit C Extra USP
removed 96.3 to 97.4% of the proteins. Among the
employed absorbents, Norit CN1 removed the most high
molecular weight proteins (97.4%) (Table 3), but this
increased rate of removal was not significantly different
when compared to the other activated carbons such as
Darco KB-B, Norit C Extra USP and Norit A Supra EUR.
While Darco KB-B and Norit CN1 were acidic, the Norit
C Extra USP and Norit A Supra EUR were neutral. In
addition, Norit CN1 and Norit C Extra USP had lower
methylene blue adsorption (29 and 22 g/100 g, respec-
tively) and Darco KB-B and Norit A Supra EUR had rela-
tively higher values (41 and 42 g/100 g, respectively). Wermeates after diafiltrations.
Table 3 The percentage of endotoxins and proteins present after the adsorption process
Endotoxin (initial: 67.44 EU/㎖) Proteins (initial 77.73 μg/㎖) Remark
Adsorbents (2%) Residual (EU/㎖) Removal (%) Residual (μg/㎖) Removal (%)
Darco KB-B 7.89 88.30 2.82 96.37 -
Norit CN1 6.70 90.07 2.01 97.41 -
Norit C Extra USP 5.40 91.99 2.09 97.32 -
Norit A Supra EUR 6.34 90.60 2.67 96.57
Norit SX Plus - - - - Colors
Norit SX 1G - - - - Colors
Norit C Gran - - - - No filtration
Norit GAC 1240+ - - - - Metal corrosion
Alumina 0.20 99.70 9.41 87.89% -
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experiments such as Norit SX Plus and 1G, Norit C Gran
and Norit GAC 1240+ for the same reasons described in
the endotoxin removal experiments, i.e. observation of
colors remained.
Removal of nucleic acid Removal of nucleic acids in
the processing broth was also evaluated by employing
various adsorbents. The results measured by the UV
spectrometer at the wavelength of 260 nm showed that
almost all the residual nucleic acids were removed re-
gardless of the state of the activated carbons (powders
vs. granule forms). The pH values of the activated car-
bons did not significantly affect removal of endotoxins,
which ranged from 88.3 to 92.0%. The pH values of the
Darco KB-B and Norit CN1 were acidic with a ≤ 15
moisture %, and the pH values of Norit C Extra USP
and Norit A Supra EUR were neutral with a ≤ moisture
10%. Up to 99.7% of the residual nucleic acids were
removed when those activated carbon adsorbents were
used. In contrast, alumina removed only 85% of the
initial residual nucleic acids. By comparing the removal
of both high molecular weight proteins and nucleic acidTable 4 Adsorbent particles and their size distributions, depe









1 0 0 0 O 90 (83%)
2 0 0.3 0 O 925 (77%)
3 2 0 0 O 11,513 (87%)
4 2 0.3 0 O 2,251 (85%)
5 2 0.3 5 X 43,100 (66%)
6 2 0.3 13 X 18,898 (22%)
7 2 0 5 O 37,932 (43%)by the activated carbons and alumina, a higher surface
to mass ratio, BET, seemed to result in a higher removal
of proteins and nucleic acids. Since the activated carbons
had a relatively high BET, i.e. higher surface to mass ra-
tios, ranging 1200 to 2050 m2/g, and alumina had a BET
value of 103 m2/g, alumina seemed to be effective in re-
moval of proteins and nucleic acids.
Removal of used adsorbents After HA purification, the
used adsorbents needed to be removed by filtration to
obtain the pure HA products. Even though all the acti-
vated carbons were removed from the processed broth,
Norit C Gran, which is a granular activated carbon,
blocked the filter during filtration when a 1% broth sam-
ple was used. To better understand the reason for this
result, particles sizes and their distributions were mea-
sured for samples containing 2% Norit C Gran and 0.3%
hyaluronic acid after stirring for 5 hr (Table 4 and
Figure 4). When Norit C Gran without the addition of
HA and stirring was used, the broth was easily filtered
through a 0.45 μm filter (PR sterile 40, Begerow Inc.,
Germany) and only 108 microparticles were observed
with a diameter of 2 μm (83%). When we added HAndent upon the conditions of HA contents and stirring
Particle(ea/mL, 1/100 dilution)
2 ~ 5 μm 5 ~ 10 μm 10 ~ 15 μm 12 ~ 25 μm Total
13 (12%) 4 (4%) 1 (1%) 0 108
178 (15%) 69 (6%) 21 (2%) 3 (0.3%) 1,196
1,301 (10%) 333 (3%) 91 (0.7%) 24 (0.2%) 13,262
292 (11%) 67 (3%) 24 (1%) 8 (0.3%) 2,642
14,748 (23%) 5,047 (8%) 1,702 (3%) 554 (1%) 65,151
23,986 (29%) 18,685 (22%) 14,451 (17%) 7,990 (10%) 84,010
28,703 (33%) 13,234 (15%) 5,576 (6%) 2,268 (3%) 87,713
Figure 4 Particle numbers and sizes under the different conditions described in Table 4.
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seemed to have become entangled, and the numbers of
particles with higher sizes increased from 108 to 1,196.
When we added the granular activated carbons to the
HA solution, the number of particles with higher sizes in-
creased by a factor of two from 1,196 to 2,642. The par-
ticle sizes were, however, still mostly less than 5 μm,
indicating that the broth obtained was still filterable in this
experiment. Significant increases in particle sizes and
numbers were observed when we stirred fermented broth
containing granular activated carbons for 5 and 13 hrs.
65,151 particles were generated by stirring for 5 hr and
their numbers increased to 84,010 after 13 hr of stirring.
Furthermore, particles with sizes greater than 5 μm also
increased from 12% to 49% under these conditions. Based
on these results, Norit C Gran and 5 hr of stirring clearly
had an effect on the particle sizes and number and 87,713Figure 5 Proliferation of MC3TC on purified HA solution with assays o
cell culture for 7 days (B, ×100).particles with smaller sizes were generated and 24% of
these were larger than 5 μm in size. These results indi-
cated that under stirring conditions, granular activated
carbons broke down. Overall, we did not observe sig-
nificant effects of pH, BET, methylene blue adsorption on
the removal of high molecular weight proteins, nucleic
acid and endotixins. However, the types of activated car-
bons and species of adsorbents significantly affected their
removals of those impurities. HA had an effect on their
breakdowns and entanglement with HA resulted in an in-
crease in particle size, which lead to blockage of the mem-
brane’s pores.
Properties of the precipitated & dry HA polymers
White HA powders were obtained using sequential pro-
cessing of precipitation of HA with 2 times acetone and
then drying in clean bench. The final yield of HA wasf CCK-8 over 7 days (A) and live and dead assay (B) after in vitro
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http://www.biomaterialsres.com/content/18/1/6measured to be about 60% when comparing the weight of
dry HA with that of the diafiltered dry weight. Its intrinsic
viscosity of the HA samples was measured to be
15–17 dL/g with a molecular weight of approximately
1,000 kDa.
Biocompatibility of HA solution
Biocompatibility of HA solution were excellent in terms
of cell proliferation and viability as observed by mea-
surement of CCK-8 and observation of their cell mor-
phologies (Figure 5). The optical density of the samples
increased from 0.15 to 0.19 to 0.58 as measured by
CCK-8 (Figure 5A) and all the cells were viable without
observation of any cell death (Figure 5B).
Conclusions
We obtained white hyaluronic acid by the processes of
fermentation and purification of the fermented broth
with filtration and by the use of adsorbents. Removal of
the fermented bacterial strains and insoluble impurities
was achieved by employing both centrifuge and filtration
using filters with a diameter of 0.6-1.5 μm and through
the addition of 3 ~ 5% earth soils. Low molecular weight
impurities were successfully removed by the ultrafilter
with a molecular cut-off of 50 KDa after repeated pro-
cesses. When we increased the recycling numbers, the
permeances of the processing broth increased but the
membrane conductivity and lactate concentration de-
creased, which indicated successful removal of impu-
rities in the broth. Further purification with adsorbents
removed nearly all the endotoxins, high molecular
weight proteins and nucleic acids from the fermented
broth. While alumina was the best adsorbent for the re-
moval of endotoxins, activated carbons such as Norit
KBB, CN1, C Extra USP, A Supra EUR were very effec-
tive in the removal of high molecular weight proteins
and nucleic acids. The granular activated carbons, Norit
C Gran, were not adequate for the purification of HA
from fermenting broth due to the breakdown of the par-
ticles and subsequent entanglement with HA. These two
effects result in the formation of a significant amount of
large particles, which block the filtering membrane. The
other activated carbon in granules, Norit GAC 1240+, in-
duced metal corrosions, which is not adequate as an ad-
sorbent. Among the employed activated carbons, the
activated carbons in powders such as Norit C Extra USP
and Norit A Supra EUR with a higher BET and neutral
pH satisfied the criteria required for pharmaceuticals by
EU. The results of HA purification using activated car-
bons indicated that the adsorbent morphology, species
and type as well as processing modes such as either with
or without stirring were critically important in obtai-
ning high quality HA. The high quality HA could be
employed as a biomaterial for pharmaceuticals, tissueengineering and medical devices as well as a carrier for
cell therapy. The results of in vitro cell culture on the
HA solution obtained by mass scale production demon-
strated its excellent cell adhesion and proliferation as
well as cell viability. These results indicated that the
choices of adequate purification processes were impor-
tant in obtaining biocompatible HA and the purified HA
polymers were excellent candidate, respectively, for their
applications to biomaterials.
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